Buurreed0694

Brugada syndrome was first described in 1992 as right precordial ST-segment elevation in patients with structurally normal hearts and sudden cardiac death. Brugada Syndrome is one of the most common reasons for sudden cardiac death (4-12%) and is a hereditary disease with an autosomal dominant pattern of transmission with nearly 300 pathogenic variants in 19 responsible genes published. The present review focuses on the diagnosis, genetics, risk stratification, and management of patients with Brugada Syndrome.

Galectin-3 is a biomarker used to detect cardiac remodelling and fibrosis. It could also potentially be a biomarker for developing new treatments. Aldosterone and galectin-3 levels and their relationship to N-terminal pro-brain natriuretic peptide (NT-proBNP) and left ventricular dilatation have not yet been studied in infants with ventricular septal defect (VSD). In this study, we aimed to investigate the biomarker feature of galectin-3 in infants with VSD.

Aldosterone, galectin-3, and NT-ProBNP levels were quantified and left ventricular diameters were measured with M mode echocardiography in infants with isolated VSD who had received heart failure treatment. The results were compared with those of healthy children of similar age and gender.

This study included 22 infants (13 girls, nine boys) with VSD who formed the patient group and 22 healthy infants (13 girls, nine boys) who formed the control group. There was a significant difference between the two groups regarding the median left ventricular end-dia stolic diameter and the median left ventricular end-systole diameter. The patient and control groups had no significant difference with respect to aldosterone levels (median values 43.5 pg/mL vs 41.3 pg/mL, respectively) (P = .851), although there was a significant difference with regard to galectin-3 levels (median values 4 vs 2.5 ng/mL, respectively) (P = .015) and NT-proBNP levels (median values 204.3 vs 94.2 pg/mL, respectively) (P = .003).

Galectin-3 increases independent of left ventricular dilatation and may have a biomarker value with similar strength as NT-proBNP in infants with VSD.

Galectin-3 increases independent of left ventricular dilatation and may have a biomarker value with similar strength as NT-proBNP in infants with VSD.

Although electrocardiography scanning is routinely performed during the employ ment of employees in business sectors and during periodic controls, there is no large-scale study in our country that scans these electrocardiography data. The purpose of this study was to analyze the resting electrocardiography properties and basal clinical characteristics of the worker groups in a wide age range working in different business lines in the heavy industry sector.

Between April 2016 and January 2020, 9102 consecutive electrocardiographs were obtained during health examinations of working in İstanbul. In this study, 8607 electrocardio graphs suitable for interpretation were included. Electrocardiographs were classified by 2 dif ferent cardiologists as major, minor anomaly, and normal according to the Minnesota code criteria.

Average age of the population was 30.47 ± 9.4 and 97% were males. A completely normal ECG was detected in 67.6%. Major electrocardiograph changes were detected in 4.6%, and minor anomalies w elec trocardiograph. In the multiple logistic regression analysis, the business line and electrocardio graph were found to be independently associated with major and minor anomalies (P=,022) Conclusion This study shows the electrocardiography findings of a large sample of Turkish workers from high-risk employment sectors. Electrocardiograph abnormalities were observed more frequently in heavy chemical industry and those who were 50 years and older. This is the first study conducted in Turkey on this subject.

Safety and effectiveness of edoxaban was demonstrated in phase III, Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE-AF-TIMI 48) trial and is being confirmed in the post-authorization Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study in patients with atrial fibrillation. However, any post-authoriza tion safety study focusing on the safety of edoxaban treatment in Turkey with a prospective design has not been performed yet. The Evaluation of Treatment Safety in Patients with Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey (ETAF-TR) study is designed to evaluate the safety and effectiveness of edoxaban treatment in atrial fibrillation in routine practice. The present article describes the design and rationale for the ETAF-TR Study.

The ETAF-TR (NCT04594915) is a national, multicenter, prospective, observational study that enrolled 858 patients from 32 centers. The primary outcome of the ETAF-TR study is any overt bleeding (consisting of major bleeding or clinically relevant nonmajor bleeding or any bleeding that does not meet this definition but is considered as overt bleeding by the par ticipating physician). Effectiveness, treatment persistence, and posology will also be evaluated in an explorative manner. The overall duration of follow-up will be 1 year; the first patient was enrolled in August 2020.

Results of ETAF-TR will add data from clinical practice to those from ENGAGE-AF trial and also ETNA-AF study. Comparing their results will enable to test the external validity of ENGAGE-AF trial in the country conditions.

Results of ETAF-TR will add data from clinical practice to those from ENGAGE-AF trial and also ETNA-AF study. Comparing their results will enable to test the external validity of ENGAGE-AF trial in the country conditions.

Percutaneous closure of atrial septal defects is challenging in cases where the device is perpendicular to the septum during the procedure. Hence, different techniques, maneuvers, and auxiliary equipment may be required. We aimed to demonstrate the effectiveness of the FlexCath steerable catheter application in percutaneous closure of atrial septal defect cases in which the device was perpendicular to the septum.

Patients with atrial septal defect who presented to our clinic between January 2017 and December 2020 and were deemed eligible for percutaneous closure were included in the study.

Atrial septal defects of 101 patients out of 110 patients were successfully closed using standard methods. Selleck Dibenzazepine Nine patients in whom it was seen if the device was perpendicular to the interatrial septum were successfully closed with FlexCath steerable catheter support. There was no statistically significant difference between patients in terms of age, gender, floopy rim, and multiple defects. In the group that was treated with FlexCath steerable catheter support, the aortic rim was smaller, and the defect diameter and the size of the atrial septal defects device were larger. The success of the procedure was 100% while using the flexcath steerable catheter in patients with the device perpendicular to the interatrial septum. There were no complica tions during the procedure.

Percutaneous closure with FlexCath steerable catheter support in difficult cases with atrial septal defects was effective in those with the atrial septal closure device being per pendicular to the interatrial septum and was performed easily without any safety issues.

Percutaneous closure with FlexCath steerable catheter support in difficult cases with atrial septal defects was effective in those with the atrial septal closure device being per pendicular to the interatrial septum and was performed easily without any safety issues.

The coronavirus disease 2019 infection is a global pandemic that has affected the whole world population. We aimed to evaluate the prognostic role of cross-sectional area, muscle index, and muscle attenuation values in computed tomography-based skeletal groups [erector spinae muscle, pectoralis muscle, and total skeletal muscle] of patients hospitalized for coronavirus disease 2019 and with at least 1 cardiovascular risk factor.

A total of 232 patients with coronavirus disease 2019 and at least 1 cardiovascular risk factor were enrolled in the study, retrospectively. The cross-sectional area, muscle index, and attenuation of erector spine muscle, pectoralis muscle, and total skeletal muscle were automatically measured on computed tomography images. The study population was assigned into tertiles on the basis of the total SMcsa index. The relationship between the values obtained and the length of hospital stay, admission to intensive care unit, the need for invasive mechani cal ventilation, and mortality was investigated.

Admission to intensive care unit, need for invasive mechanical ventilation, and mor tality were higher at tertile 3 groups than in the other groups (all P values <.001). Statistically, all muscle measurements were significantly lower in tertile 3 (P <.001). Diabetes mellitus, hypertension, and total SMcsa index were predictors of in-hospital mortality in patients with coronavirus disease 2019 on the basis of Cox regression analysis. In the Kaplan-Meier analysis for the proportion of survivors relative to the total SMcsa index, tertile 3 had the highest mortal ity (survival rates 57%, P < .001).

Sarcopenia and attendant cardiovascular comorbidities can effectively assess dis ease severity and predict outcome in patients with coronavirus disease 2019.

Sarcopenia and attendant cardiovascular comorbidities can effectively assess dis ease severity and predict outcome in patients with coronavirus disease 2019.

No study has thus far evaluated the association of controlling nutritional status (CO NUT) score and prognostic nutritional index (PNI) with prognosis in candidates listed for heart transplantation (HT). Therefore, in this study, we aimed to investigate the impact of these nutritional indices on prognosis in these candidates.

In this retrospective study, a total of 195 candidates for HT were included. Over a median follow-up period of 503.5 days, the patients were grouped as survivors (n=121) and non-survivors (n = 74). Malnutrition was defined as CONUT score ≥2 (CONUT-defined malnu trition) and PNI ≤38 (PNI-defined malnutrition).

The CONUT-defined malnutrition was observed in 19.8% and 39.2% of the survivors and non-survivors (P = .003), and the PNI-defined malnutrition was observed in 7.4% and 16.2% of the survivors and non-survivors (P = .032). The univariate analysis revealed that the CONUT score from 0 to 2 (hazard ratio [HR] 1.41, 95% confidence interval [CI] 1.11-1.79, P =.004) and PNI from 45.5 to 54.5 (HR 0.78, 95% CI 0.64-0.95, P = .001), the CONUT-defined malnutrition (HR 2.48, 95% CI 1.55-3.97, P < .001) and the PNI-defined malnutrition (HR 1.97, 95% CI 1.01-3.86, P = .04) were associated with mortality. In the multivariate adjusted models, the CO NUT-defined malnutrition was an independent predictor of mortality, whereas the PNI-defined malnutrition was not a predictor of mortality (HR 1.92, 95% CI 1.12-3.27, P = .001 and HR 1.64, 95% CI 0.80-3.40, P = .18). The log-rank test revealed that the CONUT-defined malnutri tion and the PNI-defined malnutrition were associated with decrease in survival rate.

Although both the CONUT score and the PNI score were associated with prognosis in candidates for HT, the CONUT score was superior to the PNI score in predicting mortality.

Although both the CONUT score and the PNI score were associated with prognosis in candidates for HT, the CONUT score was superior to the PNI score in predicting mortality.